BioNano Genomics Inc vs Keysight Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Keysight Technologies Inc trades at $322.57 (market cap $55.67B). The key difference: Keysight Technologies Inc is far larger — about 4217.4× BioNano Genomics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | KEYS | |
|---|---|---|
Market Cap | $13.20M | $55.67B |
Sector | Health | Technology |
52-Week High | $4.92 | $373.34 |
52-Week Low | $1.09 | $158.51 |
Enterprise Value | $15.81M | $56.01B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Keysight Technologies (KEYS) trades at $320.83, down 0.38% today, with technical indicators showing a bearish trend near key support at $317. The company reported strong Q1 2026 earnings of $2.87 per share, beating estimates of $2.32, and maintains robust profitability with a 17.31% net income margin. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Wall Street maintains a bullish outlook with a $396.56 consensus price target and 75% buy ratings, though high valuation multiples and volatile cash flows pose risks. Upside potential hinges on execution in high-growth tech sectors, while investor sentiment is tempered by near-term technical weakness and macroeconomic pressures.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →